摘要
目的:探究克拉霉素、阿奇霉素、多西环素治疗生殖道衣原体感染的临床效果。方法:选取2017年5月-2018年11月本院收治的84例生殖道衣原体感染患者作为研究对象,按随机数字表法分为试验组、对照组1和对照组2,每组28例。试验组使用克拉霉素胶囊进行治疗,对照组1使用阿奇霉素分散片进行治疗,对照组2使用盐酸多西环素肠溶胶囊进行治疗。治疗14 d后,比较三组治疗总有效率、临床症状改善时间及不良反应发生情况,比较三组感染病原体对所用药物的敏感性和耐受性。结果:试验组治疗总有效率均明显高于对照组1、2(P<0.05);试验组病原体药物敏感率均明显高于对照组1、2(P<0.05),试验组病原体药物耐受率明显低于对照组1(P<0.05);试验组临床症状改善时间均明显短于对照组1、2(P<0.05);试验组不良反应发生率均明显低于对照组1、2(P<0.05)。结论:克拉霉素治疗生殖道衣原体感染的临床效果显著,可以明显缩短患者临床症状改善时间,且安全性良好,值得临床推广应用。
Objective:To explore the clinical efficacy of Clarithromycin,Azithromycin and Doxycycline in the treatment of genital chlamydia infection.Method:A total of 84 patients with genital chlamydia infection admitted to our hospital from May 2017 to November 2018 were selected as the study objects.According to the random number table method,they were divided into experimental group,control group 1 and control group 2,28 cases in each group.The experimental group was treated with Clarithromycin Capsules,the control group 1 was treated with Azithromycin Dispersible Tablets,and the control group 2 was treated with Doxycycline Hydrochloride Enteric-soluble Capsules.After 14 d of treatment,the total effective rate,clinical symptom improvement time and adverse reactions of the three groups were compared.The sensitivity and tolerance of pathogens to the drugs of the three groups were compared.Result:The total effective rate of treatment in the experimental group were significantly higher than those in the control group 1,2(P<0.05).The sensitivity of pathogens to the drugs rate in the experimental group were significantly higher than those in the control group 1,2(P<0.05),the tolerance of pathogens to the drugs rate in the experimental group was significantly lower than that in the control group 1(P<0.05).The clinical symptom improvement time in the experimental group were significantly lower than those in the control group 1,2(P<0.05).The incidence of adverse reactions in the experimental group were significantly lower than those in the control group 1,2(P<0.05).Conclusion:Clarithromycin has significant clinical efficacy in the treatment of genital chlamydia infection.It can significantly shorten the improvement time of patients’clinical symptoms,and has good safety,which is worthy of clinical application.
作者
魏晓华
WEI Xiaohua(Shenzhen Longgang Sixth People’s Hospital,Shenzhen 518117,China)
出处
《中国医学创新》
CAS
2020年第3期117-120,共4页
Medical Innovation of China
